Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | LMNA | P02545 | 5/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 14/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | PGR | P06401 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1313918 | 0.86 | MAPT (0.42) | MAPTLMNANPSR1HTTTP53 | |
| SCHEMBL1316150 | 0.85 | MAPT (0.49) | MAPTLMNANPSR1HTTTP53 | |
| SCHEMBL17667948 | 0.84 | MAPT (0.44) | MAPTLMNANPSR1HTTTP53 | |
| SCHEMBL1315415 | 0.84 | NR3C1 (0.42) | MAPTLMNANPSR1HTTTP53 | |
| SCHEMBL1829316 | 0.84 | MAPT (0.44) | MAPTLMNANPSR1HTTTP53 | |
| SCHEMBL17667957 | 0.83 | MAPT (0.45) | MAPTLMNANPSR1HTTTP53 | |
| SCHEMBL1780365 | 0.83 | MAPT (0.41) | MAPTLMNANPSR1HTTTP53 | |
| SCHEMBL1780352 | 0.83 | MAPT (0.41) | MAPTLMNANPSR1HTTTP53 | |
| SCHEMBL1314233 | 0.83 | LMNA (0.62) | MAPTLMNANPSR1HTTTP53 | |
| SCHEMBL2350441 | 0.82 | MAPT (0.38) | MAPTLMNANPSR1HTTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580784-B2 | Method for treating a disease related to the glucocorticoid receptor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-11-12 | — | — | US | claimed |
| EP-2085388-B1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLAMINO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-09-05 | — | — | EP | claimed |
| US-20110275632-A1 | Method for preventing or treating a disease related to the glucocorticoid receptor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-10 | — | — | US | claimed |
| US-8008498-B2 | 1,2-dihydroquinoline derivative having substituted phenylamino lower alkyl group and ester-introduced phenyl group as substituents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-08-30 | — | — | US | claimed |
| US-20090298827-A1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLAMINO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-03 | — | — | US | claimed |
| EP-2085388-A1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLAMINO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | Santen Pharmaceutical Co., Ltd (JP) | 2009-08-05 | — | — | EP | claimed |
| US-8580784-B2 | Method for treating a disease related to the glucocorticoid receptor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-11-12 | — | — | US | disclosed |
| US-8426406-B2 | Glucocorticoid receptor agonist comprising 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivatives having substituted oxy group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-04-23 | — | — | US | disclosed |
| EP-2085388-B1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLAMINO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20110275632-A1 | Method for preventing or treating a disease related to the glucocorticoid receptor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
| US-8008498-B2 | 1,2-dihydroquinoline derivative having substituted phenylamino lower alkyl group and ester-introduced phenyl group as substituents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20110118260-A1 | GLUCOCORTICOID RECEPTOR AGONIST COMPRISING 2,2,4-TRIMETHYL-6-PHENYL-1,2-DIHYDROQUINOLINE DERIVATIVES HAVING SUBSTITUTED OXY GROUP | SANTEN PHARMACEUTICAL CO.,LTD. (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20090298827-A1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLAMINO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-03 | — | — | US | disclosed |
| EP-2085388-A1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLAMINO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | Santen Pharmaceutical Co., Ltd (JP) | 2009-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298827-A1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING SUBSTITUTED PHENYLAMINO LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | NR3C1, NR3C2, MC2R | MAPT 4861/4885LMNA 4444/4885NPSR1 102/4885 |
| US-20110118260-A1 | GLUCOCORTICOID RECEPTOR AGONIST COMPRISING 2,2,4-TRIMETHYL-6-PHENYL-1,2-DIHYDROQUINOLINE DERIVATIVES HAVING SUBSTITUTED OXY GROUP | NR3C1, NR3C2, MC2R | MAPT 4602/4885LMNA 4205/4885NPSR1 177/4885 |
| US-20110275632-A1 | Method for preventing or treating a disease related to the glucocorticoid receptor | NR3C1, NR3C2, NR5A1 | MAPT 3231/4885LMNA 1760/4885NPSR1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.